{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT00074737: Phase 2 Interventional Completed Acute Myelogenous Leukemia
(2004)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
INN:lixadesiran [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT02781883: Phase 2 Interventional Recruiting Acute Myeloid Leukemia (AML)
(2016)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT01940887: Phase 3 Interventional Terminated Age-Related Macular Degeneration
(2014)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT01899729: Phase 2 Interventional Completed Plaque Psoriasis
(2013)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT03974113: Phase 3 Interventional Active, not recruiting Hemophilia
(2020)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT01646489: Phase 1 Interventional Completed Hepatitis C
(2012)
Source URL:
Class:
NUCLEIC ACID
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00932100: Phase 2 Interventional Completed Acute Coronary Syndrome (ACS)
(2009)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT04544956: Phase 2 Interventional Completed Hepatitis B
(2020)
Source URL:
Class:
NUCLEIC ACID